궤양성 대장염 진단과 동시에 발견된 거대세포바이러스 대장염 1예 = Cytomegalovirus Colitis with Ulcerative Colitis in the Steroid Naïve Immunocompetent Patient

다국어 초록 (Multilingual Abstract)

Ulcerative colitis is an idiopathic chronic inflammatory bowel disease that exclusively involves the colon. It is characterized by diffuse mucosal inflammation and a recurrent course of remission and relapse. Factors such as smoking, diet, genetic factors and miocrobial infection have all been suggested as causes of ulcerative colitis. One of the important issues in the treatment of ulcerative colitis is opportunistic infection associated with the usage of corticosteroid and immunosuppresant. In most cases, opportunistic cytomegalovirus infection after treatment with corticosteroid or immunosuppressant worsens the course of ulcerative colitis. However, cytomegalovirus infection is uncommon in immunocompetent patients and it is rare in immunocompetent patients with corticosteroid naive ulcerative colitis. We report here on a case in which an immunocompetent patient was newly diagnosed with ulcerative colitis and cytomegalovirus coinfection simultaneously.

국문 초록 (Abstract)

궤양성 대장염은 대장에 국한된 미만성 점막 염증을 특징으로 하며, 악화와 호전을 반복하고 만성적으로 위장관에 염증을 일으키는 원인 불명의 질환이다. 임상적으로 혈변과 변의 긴박감을 동반하는 복부 통증으로 내원한다. 치료로 스테로이드, 메살라진, 면역억제제 등을 사용하는데, 스테로이드와 면역억제제의 사용으로 인한 기회 감염이 중요한 문제로 부각되고 있다. 궤양성 대장염의 치료를 위해 스테로이드나 면역억제제를 사용한 환자에게서 거대세포바이러스가 감염되면 궤양성 대장염이 악화된다. 그러나, 정상 면역을 가지고 있는 환자에서 거대세포바이러스 대장염은 흔하지 않다. 특히, 이전에 스테로이드를 사용하지 않은 정상면역을 가진 궤양성 대장염 환자에서 거대세포바이러스의 중복감염은 드물다. 저자들은 면역 기능이 정상인 환자에서 궤양성 대장염의 진단과 동시에 거대세포바이러스 감염이 동반된 증례를 경험하여 보고한다.

참고문헌 (Reference)

1 Farmer GW, "Viral investigations in ulcerative colitis and regional enteritis" 65 : 8-18, 1973

2 Criscuoli V, "Severe acute colitis associated with CMV: a prevalence study" 36 : 818-820, 2004

3 Papadakis KA, "Outcome of cytomegalovirus infections in patients with inflammatory bowel disease" 96 : 2137-2142, 2001

4 Iwamoto GK, "Modulation of interleukin 1 beta gene expression by the immediate early genes of human cytomegalovirus" 85 : 1853-1857, 1990

5 Kornbluth AA, "Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis" 16 : 215-218, 1993

6 Galiatsatos P, "Meta-analysis of outcome of cytomegalovirus colitis in immunocompetent hosts" 50 : 609-616, 2005

7 Ginsburg CH, "Impaired natural killer cell activity in patients with inflammatory bowel disease: evidence for a qualitative defect" 85 : 846-851, 1983

8 Goodgame RW, "Gastrointestinal cytomegalovirus disease" 119 : 924-935, 1993

9 Vogel FS, "Enhanced susceptibility of proliferating endothelium to salivary gland virus under naturally occurring and experimental conditions" 34 : 1064-1079, 1958

10 van Dorp WT, "Direct induction of MHC class I, but class II expression of endothelial cells by cytomegalovirus infection" 48 : 469-472, 1989

11 Cooper HS, "Cytomegalovirusinclusions in patients with ulcerative colitis and toxic dilatation requiring colonic resection" 72 : 1253-1256, 1977

12 Berk T, "Cytomegalovirus infection of the colon: a possible role in exacerbations of inflammatory bowel disease" 80 : 335-360, 1985

13 Begos DG, "Cytomegalovirus infection masquerading as an ulcerative colitis flare-up: case report and review of the literature" 69 : 323-328, 1996

14 Vega R, "Cytomegalovirus infection in patients with inflammatory bowel disease" 94 : 1053-1056, 1999

15 Orvar K, "Cytomegalovirus infection associated with onset of inflammatory bowel disease" 38 : 2307-2310, 1993

16 Pfau P, "Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patient" 96 : 895-899, 2001

17 Kandiel A, "Cytomegalovirus colitis complicating inflammatory bowel disease" 101 : 2857-2865, 2006

18 Powell RD, "Cytomegalic inclusion disease and ulcerative colitis; report of a case in a young adult" 30 : 334-340, 1961

19 Kim YT, "A case of cytomegalovirus colitis developed during the treatment of ulcerative colitis" 17 : 557-560, 1997